ifb-088

Small moleculeexperimental

Sephin1 is a guanabenz derivative that binds to and inhibits a regulatory subunit of the stress-induced protein phosphatase 1 (PPP1R15A), but not the constitutive PPP1R15B, and lacks beta2-adrenergic activity. Phosphorylation of eIF2α, α subunit of eukaryotic translation initiation factor 2, reduces protein synthesis and prevents the accumulation of misfolded protein in the endoplasmic reticulum (ER). PPP1R15A recruits the serine/threonine-protein phosphatase PP1 to dephosphorylate eIF2α, so inhibiting PPP1R15A activity prolongs the phosphorylation of eIF2α and aids in its prevention of the accumulation of misfolded protein. In vitro, Sephin1 protected cells from lethal protein misfolding and cytotoxic ER stress. In vivo Sephin1 prevented Charcot-Marie-Tooth 1B and ALS diseases in mice. — NCATS

Clinical trial activity

2 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jun 21, 2018 (NCT03610334)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

NC(=N)N\N=C\C1=CC=CC=C1Cl
Mol. weight
196.637 g/mol

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05508074Phase 2Nov 30, 2022CHU La Timone, InFlectis BioScience, University of Milan
NCT03610334Phase 1Jun 21, 2018Aix-University of Marseille, InFlectis BioScience, Qualissima, STRAGEN
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
InFlectis BioScienceFor profit2222018
Aix-University of MarseilleAcademic/Hospital1012018
CHU La TimoneAcademic/Hospital1012022
QualissimaFor profit1012018
STRAGENFor profit1012018
University of MilanAcademic/Hospital1012022
6 organizations
Page 1 / 1